Vanguard Group Inc. Sells 9,308 Shares of SI-BONE, Inc. (NASDAQ:SIBN)

Vanguard Group Inc. decreased its position in SI-BONE, Inc. (NASDAQ:SIBN) by 0.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,408,810 shares of the company’s stock after selling 9,308 shares during the quarter. Vanguard Group Inc. owned 5.74% of SI-BONE worth $33,772,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. FMR LLC grew its stake in SI-BONE by 103.6% during the third quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after buying an additional 1,198 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in shares of SI-BONE by 90.4% in the 3rd quarter. Janus Henderson Group PLC now owns 22,582 shares of the company’s stock worth $316,000 after acquiring an additional 10,721 shares in the last quarter. State Street Corp grew its position in SI-BONE by 5.1% during the 3rd quarter. State Street Corp now owns 1,081,871 shares of the company’s stock worth $15,125,000 after acquiring an additional 52,972 shares during the last quarter. Wellington Management Group LLP increased its holdings in SI-BONE by 3.5% during the 3rd quarter. Wellington Management Group LLP now owns 1,028,238 shares of the company’s stock valued at $14,375,000 after purchasing an additional 35,220 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in SI-BONE by 29.0% during the 3rd quarter. Jane Street Group LLC now owns 77,359 shares of the company’s stock valued at $1,081,000 after purchasing an additional 17,410 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company’s stock.

Analyst Ratings Changes

SIBN has been the topic of several research analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a report on Tuesday, February 25th. Truist Financial reiterated a “buy” rating and set a $22.00 target price (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC raised their price target on shares of SI-BONE from $20.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE presently has a consensus rating of “Buy” and an average price target of $24.40.

SI-BONE Price Performance

Shares of SIBN stock opened at $13.37 on Monday. The firm has a market cap of $567.60 million, a price-to-earnings ratio of -14.53 and a beta of 1.02. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The stock has a 50-day moving average price of $15.65 and a 200 day moving average price of $14.64.

SI-BONE (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.05. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The company had revenue of $49.00 million during the quarter, compared to analysts’ expectations of $48.87 million. Research analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Activity

In related news, insider Anthony J. Recupero sold 3,311 shares of the company’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.15, for a total value of $46,850.65. Following the completion of the sale, the insider now owns 284,555 shares in the company, valued at approximately $4,026,453.25. This represents a 1.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total value of $44,229.92. Following the transaction, the senior vice president now owns 244,878 shares in the company, valued at approximately $3,462,574.92. This trade represents a 1.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,776 shares of company stock valued at $96,644 in the last 90 days. 3.90% of the stock is owned by company insiders.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.